中文
EN
News Center
News Center
Wang Guangbu, Member of the Standing Committee of the CPC Zaozhuang Municipal Committee and Secretary of the CPC Tengzhou Municipal Committee, Visits viwit to Review Phase II Project
Author：
VIWIT
Release Time：
2026-09-30
On September 21, Wang Guangbu, Member of the Standing Committee of the CPC Zaozhuang Municipal Committee and Secretary of the CPC Tengzhou Municipal Committee, led a delegation to viwit for an on-site visit to review the progress of the company’s Phase II Project.
Dr. Keene Wei, President of viwit, and Guo Xinhai, Executive Vice President of viwit, accompanied the delegation. During the visit, Dr. Wei provided a comprehensive briefing on the project’s construction progress, viwit’s end-to-end capabilities across the pharmaceutical value chain, and the company’s strategic priorities for future development.
Phase II Project: A Core Production Unit of a Provincial Key Project
viwit’s Phase II Project, officially known as the “Industrialization Project for Chiral APIs for Magnetic Resonance Imaging (MRI) Contrast Agents and Other Products,” focuses on the large-scale production of active pharmaceutical ingredients (APIs) for gadolinium-based contrast agents.
The project has been designated as a key project in Shandong Province aimed at addressing critical gaps and strengthening areas of weakness, and is also a key component of viwit’s “One Expansion, Two New Initiatives” development program.
With a total investment of RMB 300 million, the project covers approximately 100 mu of land and adds more than 30,000 square meters of new building space. Major facilities include three specialized production workshops, seven Category A hazardous-material warehouses, and supporting utility and auxiliary facilities.
At present, the newly constructed production workshops are operationally ready, with production lines undergoing integrated commissioning, trial runs, and final preparations for commercial operation. Once fully commissioned, the project will have an annual production capacity of more than 200 metric tons of APIs for gadolinium-based contrast agents. In addition to expanding viwit’s manufacturing capacity, the project is expected to contribute to local tax revenue and create additional employment opportunities.
From APIs to Finished Drug Products: End-to-End In-House Capabilities Across the Value Chain
The Gadoterate Meglumine and Gadobutrol APIs manufactured at the Phase II facility are used directly in the production of the corresponding contrast agent drug products.
Both products have now been filed and approved in China and the United States. Gadoterate Meglumine has been included in China’s national volume-based procurement (VBP) program, while the first shipment of Gadobutrol Injection to the United States has been successfully completed.
From APIs to finished drug products, and from regulatory approval in China to supply to global markets, viwit has established integrated in-house capabilities spanning the entire R&D and manufacturing process.
This vertically integrated model not only helps reduce reliance on imports of high-end contrast agents through independently controlled manufacturing capabilities, but also strengthens the ability of China-developed contrast agents to compete in the global market.
From Established Products to Frontier Technologies: Advancing the Next Generation of Precision Therapies
Beyond its integrated API and finished-dosage-form business, viwit is also looking toward the next generation of therapeutic innovation.
Building on its capabilities in precision drug delivery technologies, viwit is actively advancing emerging technology platforms including in vivo cell engineering and gene therapy, while exploring next-generation precision therapies in areas such as immuno-oncology, autoimmune diseases, and immune system rejuvenation.
Building on Today, Investing in the Future
During the visit, Secretary Wang recognized viwit’s development and progress in recent years and encouraged the company to continue leveraging its strengths, remain focused on its core pharmaceutical and healthcare businesses, and further advance the integration of API and finished-dosage-form capabilities as well as frontier innovation.
He also encouraged viwit to continuously strengthen its core competitiveness and contribute new momentum to the high-quality development of the biopharmaceutical industry.
The completion and commissioning of the Phase II Project represent a systematic enhancement of viwit’s end-to-end capabilities and control across the pharmaceutical value chain, as well as a new starting point for the company’s continued development.
Looking ahead, viwit will remain committed to becoming a leading global pharmaceutical and healthcare platform company, built on integrated competitive advantages across the value chain and driven by technological innovation. Through high-quality products and forward-looking strategic initiatives, viwit will continue to contribute its expertise and capabilities to the advancement of the pharmaceutical and healthcare industry.